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Background: Development of compensatory mutations within the HIV p7/p1 and p1/p6 protease cleavage site
region has been observed in HIV-infected patients treated with protease inhibitors. Mechanisms of fitness
compensation may occur in HCV populations upon treatment of HCV protease inhibitors as well.
Findings: In this study, we investigated whether substitutions in protease cleavage site regions of HCV occur in
response to a treatment regimen containing the NS3/4A protease inhibitor telaprevir (TVR). Evaluation of viral
populations from 569 patients prior to treatment showed that the four NS3/4A cleavage sites were well conserved.
Few changes in the cleavage site regions were observed in the 159 patients who failed TVR combination treatment,
and no residues displayed evidence of directional selection after the acquisition of TVR-resistance.
Conclusions: Cleavage site mutations did not occur after treatment with the HCV protease inhibitor telaprevir.
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Protease inhibitors (PI) are part of the current treatment
regimens for both HIV and HCV infections. During
treatment, levels of wild-type virus sensitive to PI are
reduced, but PI-resistant variants may be selected. These
resistant variants may have a decreased binding affinity
for the PI, but also typically have a lower replicative cap-
acity, likely due to a decreased processing efficiency.
During HIV PI treatment, in addition to the primary
resistant variants observed in the catalytic site of the
protease, variants have been observed within the prote-
ase substrates of p7/p1 and p1/p6 of the Gag-Pol poly-
protein. These cis mutations in the protease substrates
compensate the protease impairment caused by the PI-
resistant mutations. Such mechanisms improve the pro-
tease and substrate interaction and the fitness of viral* Correspondence: tara_kieffer@vrtx.com
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reproduction in any medium, provided the orgenomes carrying PI-resistant variants. Additionally,
cleavage site mutations may directly contribute to resist-
ance to PIs, potentially by improving the cleavage of the
Gag region. Indeed, cleavage site variants have been
observed in the absence of primary PI resistance muta-
tions [1-4].
Phase 3 clinical studies investigating TVR combination
treatment demonstrated significant improvement of sus-
tained viral response (SVR) rates compared to peginter-
feron alfa-2a and ribavirin alone (PR) in HCV genotype
1 infected patients [5,6]. In a subset of patients who
failed to achieve SVR after a TVR-containing regimen,
TVR-resistant variants were observed in the NS3 prote-
ase, with the variants V36M and R155K observed most
commonly in subtype 1a infections and variants V36A,
T54A, and A156S/T observed most commonly in sub-
type 1b infections [7-9]. These resistant variants were
less fit than wild-type virus in vitro and in vivo [10,11].
In this study, we sought to determine if cleavage site
mutations also occur, either in the presence or absencel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Sequence Dataset
TVR-Treatment Armsa PR-Treatment Armsb
Cleavage Site 1a 1b Total 1a 1b Total
NS3-NS4A 71 45 116 26 17 43
NS4A-NS4B 71 45 116 26 17 43
NS4B-NS5Ac 34 9 43 19 9 28
NS5A-NS5Bc 34 9 43 19 9 28
a This group includes patients who failed to achieve SVR after TVR
combination treatment.
b This group includes patients who failed to achieve SVR after the control PR
treatment (i.e., patients who did not receive TVR).
c The NS5A-NS5B genomic region was not sequenced for PROVE2.
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to improve the processing capacity of the protease as
observed during HIV infection treatment.
Our study included PI treatment-naïve patients who
had chronic, genotype 1 HCV infection and were en-
rolled in Phase 2 clinical studies of TVR (PROVE1
and PROVE2) [12,13]. These studies were conducted
in full compliance with the guidelines of Good Clinical
Practice and of the World Medical Assembly Declar-
ation of Helsinki. The protocols and informed consent
forms of these studies were approved by an independ-
ent or institutional review board at each institution,
and written informed consent for publication of this
analysis was provided by all patients prior to partici-
pating in study-related activities. A copy of written
consent is available for review by the Editor-in-Chief
of this journal. Patients received various combinations
of TVR, peginterferon alfa-2a (40 kDa), and/or riba-
virin as described in detail in McHutchison et al. [12]
and Hézode et al. [13]. Population sequence analysis
of the HCV NS3/4A protease and protease cleavage
sites was performed before, during, and after treatment
as described previously [14].
The HCV serine protease NS3/4A cleaves four down-
stream substrates during HCV polyprotein translation,
which is essential for viral replication. Autocleavage of
the C terminus of NS3 from the N terminus of NS4
occurs in cis during translation of the nascent polypro-
tein chain, and is followed by cleavage of NS5A-NS5B,
NS4A-NS4B, and NS4B-NS5A [15]. In this study, se-
quence data were available from 569 patients before
treatment. Data from these patients were used to deter-
mine the expected frequency of amino acid variants at
each position within 10 residues on either side (P10 to
P10’) of each cleavage site in the non-structural region.
Patients who failed to achieve SVR after TVR combin-
ation treatment had received an average of 10.9 weeks of
TVR (± 2.75; standard deviation; n = 116). After treatment
failure, an average of 3.7 follow-up visits was available for
assessment of viral populations from each patient, allow-
ing an average of 7.7 weeks of follow-up (Additional file 1:
Table S1). During each assessment, viral population se-
quencing was performed for the entire non-structural re-
gion (PROVE1 patients; providing sequence data for all
four cleavage sites), and for the NS3-4A genomic region
(PROVE2 patients; providing sequence data for two cleav-
age sites; Table 1). Additionally, sequence data at all four
cleavage sites were available from 43 patients who had
failed to achieve SVR in the PR control arm of PROVE1,
and from 28 patients at two cleavage sites (NS3-NS4A
and NS4A-NS4B) from the control arm of PROVE2.
We calculated the probability of the observed fre-
quency (termed F) of each residue at each position
within patients who had failed to achieve SVR after TVRcombination treatment, given the frequency of that resi-
due in a TVR-naïve dataset (termed f ), with the neutral
rate of change assumed to fit a Poisson distribution and
with type I error controlled using a Bonferroni correc-
tion. The expected, i.e., treatment-naïve frequency, was
derived from the baseline frequency with which a variant
was observed in a large, semi-independent dataset that
pooled pre-treatment data from all Phase 2 and 3 studies
of telaprevir. Only those combinations of site and amino
acid wherein F> f (i.e., changes enriched in the TVR-
treatment arms relative to expectation) were analyzed
statistically.
Before treatment, the 20 amino acid residues sur-
rounding the four HCV NS3/4A cleavage sites were
highly conserved. Consistent with previous reports
[16], our data indicate that in all four NS3/4A sub-
strates, S and A predominate at the P1’ site, C or T
predominate at the P1 site, and the acidic residues E
and D predominate at the P6 site. Despite the high de-
gree of conservation within subtype 1a and 1b popula-
tions, there were characteristic differences between
subtypes 1a and 1b within the region surrounding
cleavage sites (Figure 1). That each of the four cleav-
age site regions is well conserved implies that they are
under strong stabilizing selection, and that the trans-
lated peptide they encode should be stable in estab-
lished populations. This was supported by the analysis
of 43 patients who had failed to respond to PR treat-
ment in the control arm of the studies. Indeed, during
treatment, only 1.1% (31/2840) of residues changed in
142 cleavage sites analyzed (≤ 4 cleavage sites analyzed
per patient; Table 1). Similarly, only 0.52% (33/6360)
of the residues changed in 318 cleavage site regions
analyzed from 116 patients who had failed to respond
to TVR combination treatment (≤ 4 cleavage sites ana-
lyzed per patient; Table 1).
Of the 116 patients analyzed during and after failing to
respond to TVR combination treatment, 105 had detect-
able TVR-resistant variants within NS3 (Additional file 1:
Table S1). In the TVR combination treatment arms, 10
variants in the cleavage site region were observed after
Figure 1 Baseline conservation of cleavage sites. Sequence logos (Schnieder ref [18], Crooks ref [19]) were generated from baseline (pre-
treatment) HCV sequence. Dashed lines indicate cleavage points along the HCV polyprotein, with the amino acid numbering below the cleavage
site referencing HCV genotype 1a reference strain H77 (Genbank accession NC_004102). Cartoons of proteins are not drawn to scale. (Sample size
for each sequence logo— NS3-NS4A and NS4A-NS4B: 1a = 327 patients, 1b = 242 patients; NS4B-NS5A and NS5A-NS5B: 1a = 219 patients, 1b = 108
patients).
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frequency after treatment failure than before treatment.
All of these changes were unique to a single patient
(Table 2). Not surprisingly given the rare nature of
these changes, none of the changes reached statistical
thresholds of significance, regardless of whether the
analysis utilized subtype-specific or pooled genotype 1
treatment-naïve frequencies.
Given the lack of statistically significant enrichment
of any variants in TV R treatment arms for each of the
residues analyzed, those changes in which the derived
residue in the TVR-naïve dataset is rare or absent can
most likely be explained by a genetic drift throughTable 2 Probability of occurrence of changes in TVR
combination treatment arms, based on a TVR-naïve
dataset
TVR-naïve dataset TVR-resistant dataset
Position Site AA x† X{ f(%) n† N{ F(%) Prob (F|f)
NS3 625 P7 T 0 3488 0.00 1 116 0.86 0.0322*
NS4A 9 P9’ I 4 3488 0.11 1 116 0.86 0.1165
NS4A 45 P10 H 0 3488 0.00 1 116 0.86 0.0322*
NS4B 2 P2’ L 5 3469 0.14 1 116 0.86 0.1415
NS4B 2 P2’ A 22 3469 0.63 1 116 0.86 0.3525
NS4B 4 P4’ F 5 3483 0.14 1 116 0.86 0.1410
NS4B 254 P8 G 2 776 0.26 1 43 2.33 0.0992
NS5A 2 P2’ S 2 772 0.26 1 43 2.33 0.0997
NS5A 440 P9 G 8 765 1.05 1 43 2.33 0.2868
NS5A 441 P8 P 0 761 0.00 1 43 2.33 0.0534*
NS5A 441 P8 T 3 761 0.39 2 43 4.65 0.0121*
NS5B 7 P7’ S 0 777 0.00 1 43 2.33 0.0524*
† n,x: denote the number of times each residue was observed in each dataset;
{ N,X: indicate the sample size for each dataset.
* prob- values associated with any residues which are not observed in the
TVR-naïve dataset (i.e., x = 0) are marked with an asterisk. The neutrally expected
frequency of these amino acids at these positions can only be defined as < 1/X;
therefore calculations for each of these positions assume 1 occurrence of the
residue in the TVR-naïve dataset. Probability values for these residues should
therefore be interpreted as upper bounds.bottleneck events. During TVR combination treatment,
the inhibition of viral production leads to a rapid drop
in serum HCV RNA. Due to this loss of wild-type
virus, the low baseline levels of TVR-resistant variants
are enriched in the viral population. These pre-existing
resistant variants will likely carry numerous nucleotide
changes, relative to the dominant quasispecies prior to
treatment, some of which will be coding changes. In
this way, neutral or even deleterious changes can be-
come fixed within HCV populations due to the signifi-
cant TVR-imparted selective pressure.
To further assess this hypothesis, we calculated the
difference between the rate of non-synonymous (dN) to
synonymous (dS) nucleotide changes by codon in align-
ments of the cleavage sites that included the pretreat-
ment and all on-treatment time points [17]. In this
way, the relative rates of synonymous and non-
synonymous nucleotide substitutions would capture the
time period during which the viral population would
be expected to undergo a directional selective sweep
because of the selective pressure of the inhibitor.
Under this model, a normalized dN -dS difference that
is significantly greater than 0 suggests that directional
selective pressure is acting on the codon, whereas
values less than 0 suggest stabilizing selection. No
codon had evidence for directional selection during
treatment (median p-value: 0.99938; range: 0.39, 1), and
indeed, the maximum difference between dN and dS
was only 0.37 (median: -1.3; range: -6.75, 0.37). These
data support that interpretation that HCV cleavage site
regions within the non-structural region of the poly-
protein are under strong stabilizing selection, and that
changes observed during treatment reflect stochastic
events rather than directional selection.
In this study, we assessed whether changes in any of
the four NS3/4A protease cleavage sites were a signifi-
cant mechanism of viral fitness improvement during
TVR treatment in the presence or absence of PI-
resistant variants. Our data showed that no amino acid
in the 20 residues surrounding the cleavage sites
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tory mutations.
Additional file
Additional file 1: Table S1. Individual patient data in the TVR
combination treatment arms.
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